More than 90 billion synthetic compounds and growing.
International expert team located in North America, Asia and Europe.
Bioinformatics system to collect, process and analyze data and facilitate involvement of the client to make collective decisions.
Proven success with nano-molar hits in various target classes.
Flexible business model to accommodate different needs.
Highlight of Lab & Equipment
1,300+ square meters DEL lab designed for library production & screening.
WuXi Core Strength
On the basis of its strong chemistry capability, WuXi has built high quality and high diversity libraries. Covering the majority of the med chem space, the libraries have been built around 30,000 building blocks and 4,000 scaffolds, many of which are WuXi-customized structures.
WuXi utilizes a proprietary informatics system to facilitate data mining and customer involvement in decision making.
WuXi’s end-to-end platform enables smooth transition from DEL hit to hit validation, leading to downstream medicinal chemistry activities.
WuXi Core Platform
General Work Flow for DEL Screening
DEL Service We Offer
Library Production Service
25,000+ building blocks in stock
Unique multiple on-DNA reactions to build various chemical bonds
Ability to help customers design custom library and validate building blocks
Robust quality control procedures
Final library can be delivered to customer site or stored with WuXi for downstream screening
Affinity Screening Service
100+ libraries (4000+ scaffolds) with 90 billion compounds all in one package
Flexible business model tailored to your specific needs
4 weeksfrom protein to hit
State-of-the-art informatics to decipher the most from screening results
Dedicated team with 17+ years experience for custom synthesis
Comprehensive bioassay platform and ability to assay development
Business Model Options
Service request flexibility:
1) Customized DEL library synthesis only
2) Selection against WuXi’s Libraries only
3) Both customized library synthesis and selections
Multiple business models to fit customers at different stages of financing and research. Royalty and milestones are not necessary.
Instant access to 90 billion molecules at affordable price.